Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical Updates

In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.

Faculty:

• Pedro C. Barata, MD, MSc
  Assistant Professor, Deming Department of Medicine
  Division of Hematology/Oncology, Genitourinary Cancers, Tulane University

Register